Ronald Li
CEO,
Medera
United States
As CEO of Medera, Dr. Ronald Li is an academic-turned biotech executive with track records in fundraising, public listing, M&A, privatisation, joint ventures and licensing, etc. He founded Novoheart, which was listed on Toronto Stock Exchange before privatisation by Medera. Dr. Li is an internationally recognized expert in cardiac electrophysiology, human heart cell/tissue engineering and pluripotent stem cells with over 200 peer-reviewed publications. Prior to founding Medera, Dr. Li was Assistant Professor at John Hopkins University, Associate Professor of University of California, Davis, Full Professor at Icahn School of Medicine at Mount Sinai in Manhattan, and Center Director of Ming-Wai Lau Center for Reparative Medicine at the Karolinska Institutet. Dr. Li's awards and accolades include being a two-time recipient of the Top Young Faculty Award of Johns Hopkins, Top Young Investigator and Top Postdoc Fellow of Johns Hopkins, Young Investigator Award 1st Prize of Heart Rhythm Society, American Heart Association Best Study of 2005 and Groundbreaking Study of 2006 for his work on the first genetically engineered human pluripotent stem cell-derived heart cells as well as cell- and gene-based biopacemakers. He has been named Distinguished Visiting Professor of University of Toronto and Distinguished Alumnus of University of Waterloo.
Sessions
-
10-Feb-2025Medera Biopharm
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}